FDA con­tin­ues to ques­tion Arde­lyx CKD drug's ef­fect on clin­i­cal out­comes ahead of ad­comm meet­ing

Arde­lyx is like­ly to face a hos­tile FDA ad­comm to­mor­row as out­side ex­perts weigh whether the po­ten­tial chron­ic kid­ney dis­ease drug ac­tu­al­ly pro­vides a clin­i­cal­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER